[go: up one dir, main page]

DK0531415T3 - Fremgangsmåde til behandling af alkoholisme med balmefen - Google Patents

Fremgangsmåde til behandling af alkoholisme med balmefen

Info

Publication number
DK0531415T3
DK0531415T3 DK91910595.7T DK91910595T DK0531415T3 DK 0531415 T3 DK0531415 T3 DK 0531415T3 DK 91910595 T DK91910595 T DK 91910595T DK 0531415 T3 DK0531415 T3 DK 0531415T3
Authority
DK
Denmark
Prior art keywords
balmfef
treating alcoholism
alcoholism
treating
alcoholics
Prior art date
Application number
DK91910595.7T
Other languages
English (en)
Inventor
John D Sinclair
Harry Scheinin
Risto Lammintausta
Original Assignee
Orion Yhtymae Oy
Alko Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtymae Oy, Alko Group Ltd filed Critical Orion Yhtymae Oy
Application granted granted Critical
Publication of DK0531415T3 publication Critical patent/DK0531415T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
DK91910595.7T 1990-06-04 1991-05-10 Fremgangsmåde til behandling af alkoholisme med balmefen DK0531415T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene

Publications (1)

Publication Number Publication Date
DK0531415T3 true DK0531415T3 (da) 1996-12-09

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91910595.7T DK0531415T3 (da) 1990-06-04 1991-05-10 Fremgangsmåde til behandling af alkoholisme med balmefen

Country Status (19)

Country Link
US (1) US5086058A (da)
EP (1) EP0531415B1 (da)
JP (1) JP3059213B2 (da)
AT (1) ATE145329T1 (da)
AU (1) AU642748B2 (da)
CA (1) CA2084519C (da)
DE (1) DE69123247T2 (da)
DK (1) DK0531415T3 (da)
ES (1) ES2097209T3 (da)
FI (1) FI925513A0 (da)
GR (1) GR3022289T3 (da)
HU (1) HU210637B (da)
IE (1) IE77333B1 (da)
LT (1) LT3893B (da)
LV (1) LV10190B (da)
NZ (1) NZ238391A (da)
RU (1) RU2090190C1 (da)
WO (1) WO1991018605A1 (da)
ZA (1) ZA914185B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
PT1685839E (pt) 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
EP1248800A2 (en) * 1999-11-30 2002-10-16 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
WO2001058447A1 (en) 2000-02-08 2001-08-16 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
RU2227004C2 (ru) * 2000-06-16 2004-04-20 Писаренко Фаля Юрьевич Способ лечения наркологической зависимости
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
CN1273075C (zh) * 2001-07-13 2006-09-06 爱科来株式会社 分析用具、具备分析用具的浓度测定装置用的穿刺元件一体化安装体及体液采取用具
AU2002316738B2 (en) * 2001-07-18 2009-01-08 Euro-Celtique S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
ES2326794T3 (es) 2001-08-06 2009-10-20 Euro-Celtique S.A. Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
WO2003015783A1 (en) * 2001-08-14 2003-02-27 Biotie Therapies Corporation Method of treating alcoholism or alcohol abuse
RU2215527C2 (ru) * 2001-09-28 2003-11-10 Областная наркологическая больница Способ купирования алкогольного абстинентного синдрома, алкогольного делирия, острого алкогольного галлюциноза
RU2200556C1 (ru) * 2001-12-05 2003-03-20 Северцев Владимир Алексеевич Лекарственная форма налтрексона
PT2425824T (pt) 2002-04-05 2017-08-23 Mundipharma Farmacêutica Lda Preparação farmacêutica contendo oxicodona e naloxona
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
EP1613324A2 (en) * 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
PT2484346T (pt) 2006-06-19 2017-04-26 Alpharma Pharmaceuticals Llc Composições farmacêuticas
BRPI0718420A2 (pt) 2006-10-20 2013-11-12 Cpd Llc Método de restabelecimento do efeito da incretina
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2009088673A2 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
PL2307420T3 (pl) * 2008-04-24 2012-04-30 Janssen Pharmaceutica Nv Proleki diestrowe nalmefenu
ME01319B (me) * 2008-04-24 2013-12-20 Janssen Pharmaceutica Nv Prolijekovi nalmefena
MX2011000155A (es) * 2008-07-07 2011-03-01 Euro Celtique Sa Uso de antagonistas opioides para el tratamiento de retencion urinaria.
RU2393864C1 (ru) * 2008-12-29 2010-07-10 Руслан Дмитриевич Илюк Средство для профилактики и лечения алкоголизма и опиоидной наркомании
ME03298B (me) 2009-03-10 2019-07-20 Euro Celtique Sa Farmaceutske kombinacije sa trenutnim oslobađanjem које obuhvataju oksikodon i nalokson
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
CN105517551A (zh) 2013-07-23 2016-04-20 欧洲凯尔特公司 用于在患有疼痛和导致肠生态失调和/或提高肠细菌移位风险之疾病的患者中治疗疼痛的羟考酮与纳洛酮的组合
JP6797691B2 (ja) * 2014-04-22 2020-12-09 大塚製薬株式会社 ブレクスピプラゾールとナルメフェンの組み合わせ剤及び物質関連障害を治療するためのその用途
EP3215154B1 (en) 2014-11-07 2020-01-29 Regents of the University of Minnesota Salts and compositions useful for treating disease
BR112018071705A2 (pt) * 2016-04-22 2019-02-19 Taiwanj Pharmaceuticals Co., Ltd. método de profilaxia ou tratamento de nafld, nash ou ash, uso de um composto de fórmula (i), e composto de fórmula (i)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Also Published As

Publication number Publication date
FI925513A7 (fi) 1992-12-04
JPH06506665A (ja) 1994-07-28
ATE145329T1 (de) 1996-12-15
CA2084519C (en) 1999-02-09
AU7974091A (en) 1991-12-31
AU642748B2 (en) 1993-10-28
IE77333B1 (en) 1997-12-03
CA2084519A1 (en) 1991-12-05
LTIP1486A (en) 1995-09-25
ZA914185B (en) 1992-07-29
US5086058A (en) 1992-02-04
FI925513L (fi) 1992-12-04
RU2090190C1 (ru) 1997-09-20
EP0531415B1 (en) 1996-11-20
WO1991018605A1 (en) 1991-12-12
FI925513A0 (fi) 1992-12-04
HU9203835D0 (en) 1993-03-29
JP3059213B2 (ja) 2000-07-04
EP0531415A1 (en) 1993-03-17
LV10190B (en) 1995-06-20
DE69123247D1 (de) 1997-01-02
DE69123247T2 (de) 1998-01-15
LT3893B (en) 1996-04-25
HU210637B (en) 1995-06-28
NZ238391A (en) 1997-06-24
ES2097209T3 (es) 1997-04-01
HUT65523A (en) 1994-06-28
LV10190A (lv) 1994-10-20
IE911888A1 (en) 1991-12-04
GR3022289T3 (en) 1997-04-30

Similar Documents

Publication Publication Date Title
DK0531415T3 (da) Fremgangsmåde til behandling af alkoholisme med balmefen
RU92016403A (ru) Способ лечения алкоголизма налмефеном
FI963571L (fi) Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi
NO960878D0 (no) Underjordisk tank med dobbelt komposittvegg, samt fremgangsmåte for dens fremstilling
DE59308000D1 (de) Immunoassay zum nachweis von kollagen oder kollagenfragmenten
DE59004541D1 (de) Verfahren zum Vermindern des Alkoholgehaltes alkoholischer Getränke.
DE69533988D1 (de) Verfahren zum blokieren von sec-rezeptoren
DE68912312D1 (de) Vorrichtung zum schichtweisen herstellen von getränken.
FI943350L (fi) Menetelmä muotokappaleiden, joilla on lämpöä varastoivia ominaisuuksia, valmistamiseksi
MY119686A (en) Sequential distillation process for removing tetrahydroazepine from aminocapronitrile and/or hexamethylenediamine
DK0857206T3 (da) Krystallinsk cellulase samt fremgangsmåde til fremstilling af samme
GR3015586T3 (en) Process for producing fuel oil and gas by cracking waste rubber.
FI940969L (fi) Menetelmä vedenerottuvuuden parantamiseksi mäntyöljyn valmistusprosessissa sekä menetelmä mäntyöljyn valmistamiseksi
ES2121554A1 (es) Procedimiento de obtencion de 14-hidroximorfinas mediante fotooxidacion de alcaloides morfinicos con sistema alcoxidienico en el anillo c.
HUT69760A (en) Process for the preparation of in alfa-position by alkyl group substituted aldehyde
DK0556829T3 (da) Fremgangsmåde til formindskelse af cyklustiden ved flerhulheds-strækblæsestøbning
DK0805847T3 (da) Alkoholholdig instant-drikkeblanding, dens fremstilling og anvendelse
NO983255D0 (no) FremgangsmÕte ved fremstilling av pall, samt pall fremstilt ved fremgangsmÕten
GR3024442T3 (en) Method to purify streptolysin o, intact streptolysin o obtainable by this method and its use
FI891652A7 (fi) Menetelmä proteiinien valmistamiseksi, joiden N-terminaali alkaa proliinilla
DE69212636D1 (de) Antioxidantienherstellung
RU2005191C1 (ru) Способ установки анкера
KR970008196U (ko) 인서트 사출방식에 의한 물안경
DE69410898D1 (de) Verfahren zur herstellung von n,n,-disubstituiertem aminophenol
EP0612797A3 (en) Resin modification process.